ScreenerHero

TCRTAlaunos Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · alaunos.com
1.760USD-6.38%Mkt Cap: 4.47M $P/E: —

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.47M $
Enterprise Value4.32M $
Revenue (TTM)3.00K $
Gross Profit-1.44M $
Net Income (TTM)-4.18M $
Revenue/Share0.0010 USD
Last Price1.760 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.00
PEG0.58
EV/EBITDA-1.05
EV/Revenue1440.25
P/S1524.29
P/B3.32
EPS (TTM)-1.68
EPS (Forward)-0.60
52W Range
1.6703% of range4.590
52W High4.590 USD
52W Low1.670 USD
Profitability
Gross Margin0.00%
Oper. Margin-138166.67%
EBITDA Margin0.00%
Profit Margin-83520.00%
ROE-193.96%
ROA-140.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.87M $
CapEx (TTM)98.00K $
FCF Margin-71320.83%
FCF Yield-47.85%
Net Debt-354.00K $
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity—
Current Ratio1.63
Quick Ratio0.59
Book Value/Sh0.5420 USD
Cash/Share0.1460 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 18, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.54M
Float1.86M
Insiders15.91%
Institutions5.08%
Short Interest
Short Ratio0.8d
Short % Float0.44%
Short % Out.0.40%
Shares Short9.78K
Short (prev mo.)14.67K
Technical
SMA 502.044 (-13.9%)
SMA 2002.756 (-36.1%)
Beta-0.96
S&P 52W Chg18.16%
Avg Vol (30d)9.16K
Avg Vol (10d)11.55K
Technical Indicators
RSI (14)29.9
MACD-0.0546
MACD Signal-0.0500
MACD Hist.-0.0045
BB Upper2.049 USD
BB Middle1.929 USD
BB Lower1.809 USD
BB Width12.42%
ATR (14)0.0955 USD
Vol Ratio (20d)1.76x